Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
Report: Mylan Could See Sweetened Bid From Teva Pharmaceutical
Could M&A Boost Pfizer More? Jefferies Thinks So
Health Care Stocks For A Dividend Growth Portfolio - Part 2 (Seeking Alpha)
Related IPXL
5 New Biotech Developments Worth Watching
Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

Around the Web, We're Loving...